Nuvation Bio Appoints David Liu, M.D., Ph.D., as Chief Medical Officer and Kerry Wentworth as Chief Regulatory Officer

Dr. Liu is a clinical leader who brings expertise in the discovery, development, and regulatory approval of oncology therapies worldwide

Ms. Wentworth has over two decades of industry experience in... | July 18, 2022

Related Keywords

China ,Beijing ,Shanghai ,David Liu ,Pacira Biosciences ,Nuvation Bio ,Quality At Agenus Inc ,Massachusetts Institute Of Technology ,University Of Toledo ,Genelabs Technologies Inc ,Oncology Global Clinical Research ,Global Prostate Cancer Program ,Pediatric Clinical Development ,Nuvation Bio Inc ,University Peking School Of Medicine ,Bristol Myers Squibb ,Regulatory Affairs At Genzyme ,Translational Research ,University Of New Hampshire ,Chief Medical Officer ,Kerry Wentworth ,Chief Regulatory ,New Drug Application ,Chief Regulatory Officer ,Flexion Therapeutics ,David Hung ,Chief Executive Officer ,After Bristol Myers Squibb ,Global Lead Physician ,Massachusetts Institute ,Beijing Medical University ,Peking University School ,Vice President ,Genelabs Technologies ,Regulatory Affairs ,Nuvation Bio Inc Stock Exchange ,News ,Information ,Press Release ,Liu ,Us ,Linical ,Leader ,Who ,Rings ,Expertise ,N ,The ,End ,Egulatory ,Approval ,F ,Ncology ,Therapies ,Wentworth ,Gas ,Dover ,Two ,Ecades ,Industry ,Xperience Nuvb Us67080n1019 ,